258 related articles for article (PubMed ID: 28531261)
41. Effectiveness of Human Papillomavirus Vaccination on Prevalence of Vaccine Genotypes in Young Sexually Active Women in France.
Heard I; Tondeur L; Arowas L; Demazoin M; Falguières M; Parent Du Chatelet I;
J Infect Dis; 2017 Mar; 215(5):757-763. PubMed ID: 28011911
[TBL] [Abstract][Full Text] [Related]
42. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study.
Castanon A; Landy R; Pesola F; Windridge P; Sasieni P
Lancet Public Health; 2018 Jan; 3(1):e34-e43. PubMed ID: 29307386
[TBL] [Abstract][Full Text] [Related]
43. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
44. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections.
Safaeian M; Porras C; Schiffman M; Rodriguez AC; Wacholder S; Gonzalez P; Quint W; van Doorn LJ; Sherman ME; Xhenseval V; Herrero R; Hildesheim A;
J Natl Cancer Inst; 2010 Nov; 102(21):1653-62. PubMed ID: 20944077
[TBL] [Abstract][Full Text] [Related]
45. Surveillance of effects of HPV vaccination in Belgium.
Arbyn M; Broeck DV; Benoy I; Bogers J; Depuydt C; Praet M; Sutter PD; Hoorens A; Hauben E; Poppe W; Van Ranst M; Delvenne P; Gofflot S; Pétein M; Engelen F; Vanneste A; Beeck LO; Damme PV; Temmerman M; Weyers S
Cancer Epidemiol; 2016 Apr; 41():152-8. PubMed ID: 26895623
[TBL] [Abstract][Full Text] [Related]
46. The projected timeframe until cervical cancer elimination in Australia: a modelling study.
Hall MT; Simms KT; Lew JB; Smith MA; Brotherton JM; Saville M; Frazer IH; Canfell K
Lancet Public Health; 2019 Jan; 4(1):e19-e27. PubMed ID: 30291040
[TBL] [Abstract][Full Text] [Related]
47. Human papillomavirus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy.
Mariani L; Monfulleda N; Alemany L; Vizza E; Marandino F; Vocaturo A; Benevolo M; Quirós B; Lloveras B; Klaustermeier JE; Quint W; de Sanjosé S; Bosch FX
BMC Cancer; 2010 Jun; 10():259. PubMed ID: 20525370
[TBL] [Abstract][Full Text] [Related]
48. Cervical cancers associated with human papillomavirus types 16, 18 and 45 are diagnosed in younger women than cancers associated with other types: a cross-sectional observational study in Wales and Scotland (UK).
Powell N; Cuschieri K; Cubie H; Hibbitts S; Rosillon D; De Souza SC; Molijn A; Quint W; Holl K; Fiander A
J Clin Virol; 2013 Nov; 58(3):571-4. PubMed ID: 24051043
[TBL] [Abstract][Full Text] [Related]
49. Prevalence of vaccine and non-vaccine human papillomavirus types among women in Accra and Kumasi, Ghana: a cross-sectional study.
Debrah O; Agyemang-Yeboah F; Donkoh ET; Asmah RH
BMC Womens Health; 2021 Oct; 21(1):372. PubMed ID: 34702246
[TBL] [Abstract][Full Text] [Related]
50. [Cervical cancer prevention: the impact of HPV vaccination].
Monsonégo J
Gynecol Obstet Fertil; 2006 Mar; 34(3):189-201. PubMed ID: 16529969
[TBL] [Abstract][Full Text] [Related]
51. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
[TBL] [Abstract][Full Text] [Related]
52. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs.
Dillner J; Nygård M; Munk C; Hortlund M; Hansen BT; Lagheden C; Liaw KL; Kjaer SK
Vaccine; 2018 Jun; 36(26):3820-3829. PubMed ID: 29778519
[TBL] [Abstract][Full Text] [Related]
53. Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine.
Petry KU; Bollaerts K; Bonanni P; Stanley M; Drury R; Joura E; Kjaer SK; Meijer CJLM; Riethmuller D; Soubeyrand B; Van Damme P; Bosch X
Hum Vaccin Immunother; 2018 Jul; 14(7):1800-1806. PubMed ID: 29553886
[TBL] [Abstract][Full Text] [Related]
54. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
[TBL] [Abstract][Full Text] [Related]
55. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
56. HPV types and variants among cervical cancer tumors in three regions of Tunisia.
KrennHrubec K; Mrad K; Sriha B; Ben Ayed F; Bottalico DM; Ostolaza J; Smith B; Tchaikovska T; Soliman AS; Burk RD
J Med Virol; 2011 Apr; 83(4):651-7. PubMed ID: 21328380
[TBL] [Abstract][Full Text] [Related]
57. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
58. Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria.
Borena W; Grünberger M; Widschwendter A; Kraxner KH; Marth E; Mayr P; Meier J; Ruth N; Guerrero AT; Marth C; Holm-von Laer D
BMC Public Health; 2016 Aug; 16(1):889. PubMed ID: 27565569
[TBL] [Abstract][Full Text] [Related]
59. Association Between Common Vaginal Infections and Cervical Non-Human Papillomavirus (HPV) 16/18 Infection in HPV-Vaccinated Women.
Hu SY; Tsang SH; Chen F; Pan QJ; Zhang WH; Hong Y; Sampson JN; Hildesheim A; Zhao FH; Kreimer AR
J Infect Dis; 2021 Feb; 223(3):445-451. PubMed ID: 32614401
[TBL] [Abstract][Full Text] [Related]
60. Changes in genital Human Papillomavirus (HPV) prevalence among urban females a decade after the Malaysian HPV vaccination program.
Khoo SP; Muhammad Ridzuan Tan NA; Rajasuriar R; Nasir NH; Gravitt P; Ng CW; Woo YL
PLoS One; 2022; 17(12):e0278477. PubMed ID: 36538522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
